(Q35180791)

7 August 2017

1 reference

title

GABA-ergic drugs: exit stage left, enter stage right (English)

1 reference

7 August 2017

1

Heather Ashton

1 reference

7 August 2017

Allan H Young

2

1 reference

PubMed ID

12870563

7 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Journal of Psychopharmacology

7 August 2017

1 reference

7 August 2017

17

1 reference

7 August 2017

174-178

1 reference

7 August 2017

2

1 reference

A double-blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users.

7 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

3-substituted GABA analogs with central nervous system activity: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

The use of tiagabine in affective disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Gabapentin use in benzodiazepine dependence and detoxification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

The new generation of GABA enhancers. Potential in the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Physical dependence on zopiclone: case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Chronic use of benzodiazepines and psychomotor and cognitive test performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Newer antiepileptic drugs in bipolar disorder: rationale for use and role in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Safety review of adult clinical trial experience with lamotrigine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Treatment of social phobia with gabapentin: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Placebo-controlled study of gabapentin treatment of panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Study is needed of visual field defects associated with any long term antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Low serum cholesterol and suicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Anticonvulsants: aspects of their mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

A summary of mechanistic hypotheses of gabapentin pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Benzodiazepine withdrawal symptoms and propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

Discontinuation symptoms and psychotropic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881103017002004

10.1177/0269881103017002004

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12870563